Madrigal Pharmaceuticals, Inc. MDGL Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported unrealized losses on investments (before tax) of $401K in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) increased by 414.1% year-over-year, from $78K to $401K.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax)?
- Over 3 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s unrealized losses on investments (before tax) has grown at a -18.5% compound annual growth rate (CAGR), from $37K to $20K.